S&P 500   3,254.06 (-1.86%)
DOW   26,864.01 (-1.55%)
QQQ   266.01 (-2.37%)
AAPL   107.89 (-3.51%)
MSFT   202.00 (-2.61%)
FB   250.01 (-1.86%)
GOOGL   1,414.55 (-3.10%)
AMZN   3,017.28 (-3.57%)
NVDA   490.19 (-3.03%)
TSLA   380.56 (-10.29%)
BABA   273.53 (-0.64%)
CGC   14.40 (-10.22%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.06 (-3.40%)
T   28.02 (-1.72%)
F   6.71 (-1.03%)
ACB   5.24 (-28.42%)
GILD   63.50 (+0.16%)
NFLX   473.58 (-3.58%)
DIS   123.75 (-2.72%)
BAC   23.60 (-1.42%)
BA   152.95 (-2.46%)
S&P 500   3,254.06 (-1.86%)
DOW   26,864.01 (-1.55%)
QQQ   266.01 (-2.37%)
AAPL   107.89 (-3.51%)
MSFT   202.00 (-2.61%)
FB   250.01 (-1.86%)
GOOGL   1,414.55 (-3.10%)
AMZN   3,017.28 (-3.57%)
NVDA   490.19 (-3.03%)
TSLA   380.56 (-10.29%)
BABA   273.53 (-0.64%)
CGC   14.40 (-10.22%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.06 (-3.40%)
T   28.02 (-1.72%)
F   6.71 (-1.03%)
ACB   5.24 (-28.42%)
GILD   63.50 (+0.16%)
NFLX   473.58 (-3.58%)
DIS   123.75 (-2.72%)
BAC   23.60 (-1.42%)
BA   152.95 (-2.46%)
S&P 500   3,254.06 (-1.86%)
DOW   26,864.01 (-1.55%)
QQQ   266.01 (-2.37%)
AAPL   107.89 (-3.51%)
MSFT   202.00 (-2.61%)
FB   250.01 (-1.86%)
GOOGL   1,414.55 (-3.10%)
AMZN   3,017.28 (-3.57%)
NVDA   490.19 (-3.03%)
TSLA   380.56 (-10.29%)
BABA   273.53 (-0.64%)
CGC   14.40 (-10.22%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.06 (-3.40%)
T   28.02 (-1.72%)
F   6.71 (-1.03%)
ACB   5.24 (-28.42%)
GILD   63.50 (+0.16%)
NFLX   473.58 (-3.58%)
DIS   123.75 (-2.72%)
BAC   23.60 (-1.42%)
BA   152.95 (-2.46%)
S&P 500   3,254.06 (-1.86%)
DOW   26,864.01 (-1.55%)
QQQ   266.01 (-2.37%)
AAPL   107.89 (-3.51%)
MSFT   202.00 (-2.61%)
FB   250.01 (-1.86%)
GOOGL   1,414.55 (-3.10%)
AMZN   3,017.28 (-3.57%)
NVDA   490.19 (-3.03%)
TSLA   380.56 (-10.29%)
BABA   273.53 (-0.64%)
CGC   14.40 (-10.22%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.06 (-3.40%)
T   28.02 (-1.72%)
F   6.71 (-1.03%)
ACB   5.24 (-28.42%)
GILD   63.50 (+0.16%)
NFLX   473.58 (-3.58%)
DIS   123.75 (-2.72%)
BAC   23.60 (-1.42%)
BA   152.95 (-2.46%)
Log in
OTCMKTS:INVVY

INDIVIOR PLC/S Stock Forecast, Price & News

$9.19
-1.06 (-10.34 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$8.61
Now: $9.19▼
$15.00
50-Day Range
$7.75
MA: $9.78▼
$11.75
52-Week Range
$2.23
Now: $9.19▼
$40.00
Volume348,871 shs
Average Volume141,349 shs
Market Capitalization$1.35 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.13
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Read More
INDIVIOR PLC/S logo

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.76 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:INVVY
Previous SymbolNASDAQ:INVVY
CUSIPN/A
CIKN/A
Webwww.indivior.com
Phone804-379-1090

Debt

Debt-to-Equity Ratio7.05
Current Ratio1.75
Quick Ratio1.63

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio83.55
P/E GrowthN/A

Sales & Book Value

Annual Sales$785 million
Price / Sales1.72
Cash Flow$1.62 per share
Price / Cash Flow5.69
Book Value$1.43 per share
Price / Book6.43

Profitability

EPS (Most Recent Fiscal Year)$1.15
Net Income$134 million
Net Margins-13.57%
Return on Equity47.66%
Return on Assets5.31%

Miscellaneous

Employees915
Outstanding Shares146,697,000
Market Cap$1.35 billion
Next Earnings Date9/23/2020 (Estimated)
OptionableNot Optionable
$9.19
-1.06 (-10.34 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INVVY News and Ratings via Email

Sign-up to receive the latest news and ratings for INVVY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











INDIVIOR PLC/S (OTCMKTS:INVVY) Frequently Asked Questions

How has INDIVIOR PLC/S's stock price been impacted by COVID-19 (Coronavirus)?

INDIVIOR PLC/S's stock was trading at $2.84 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INVVY stock has increased by 223.6% and is now trading at $9.19.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of INDIVIOR PLC/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INDIVIOR PLC/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for INDIVIOR PLC/S.

When is INDIVIOR PLC/S's next earnings date?

INDIVIOR PLC/S is scheduled to release its next quarterly earnings announcement on Wednesday, September 23rd 2020.
View our earnings forecast for INDIVIOR PLC/S.

Who are some of INDIVIOR PLC/S's key competitors?

Some companies that are related to INDIVIOR PLC/S include Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), United Therapeutics (UTHR), Arrowhead Pharmaceuticals (ARWR), HUTCHISON CHINA/S (HCM), Zai Lab (ZLAB), MorphoSys (MOR), Arena Pharmaceuticals (ARNA), Evotec (EVTCY), FibroGen (FGEN), Allakos (ALLK), Legend Biotech (LEGN) and Reata Pharmaceuticals (RETA).
View all competitors.

Who are INDIVIOR PLC/S's key executives?

INDIVIOR PLC/S's management team includes the following people:
  • Mr. Shaun Thaxter, CEO & Exec. Director
  • Mr. Mark Crossley, CFO & Exec. Director
  • Dr. Christian Heidbreder, Chief Scientific Officer
  • Mr. Ingo Elfering, Chief Information & Innovation Officer
  • Mr. Jason Thompson, VP of Investor Relations

What is INDIVIOR PLC/S's stock symbol?

INDIVIOR PLC/S trades on the OTCMKTS under the ticker symbol "INVVY."

How do I buy shares of INDIVIOR PLC/S?

Shares of INVVY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is INDIVIOR PLC/S's stock price today?

One share of INVVY stock can currently be purchased for approximately $9.19.

How big of a company is INDIVIOR PLC/S?

INDIVIOR PLC/S has a market capitalization of $1.35 billion and generates $785 million in revenue each year. The company earns $134 million in net income (profit) each year or $1.15 on an earnings per share basis. INDIVIOR PLC/S employs 915 workers across the globe.

What is INDIVIOR PLC/S's official website?

The official website for INDIVIOR PLC/S is www.indivior.com.

How can I contact INDIVIOR PLC/S?

INDIVIOR PLC/S's mailing address is 10710 Midlothian Turnpike, North Chesterfield VA, 23235. The company can be reached via phone at 804-379-1090 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.